Investment Bank Initiates Coverage of Caliper with Outperform Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Wedbush Securities has initiated coverage of Caliper Life Sciences with an 'Outperform' rating and a 12-month price target of $9.

Wedbush analyst Zarak Kurshid cited Caliper's products for the sequencing and diagnostic markets as key drivers for the firm. He also said that recent divestitures provide a "cleaner story" as the firm moves toward sustainable profitability.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.